Press release
Intrahepatic Cholangiocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Basilea Pharmaceutica, Virogin Biotech Ltd, TriSalus Life
Intrahepatic Cholangiocarcinoma Pipeline Analysis
According to DelveInsight, over 18 leading companies are actively engaged in the development of more than 20 therapeutic candidates for the treatment of intrahepatic cholangiocarcinoma.
Intrahepatic Cholangiocarcinoma Overview:
Intrahepatic cholangiocarcinoma (ICC) is the second most common type of liver cancer, representing around 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts located within the liver tissue, near the secondary biliary branches. Most ICC cases are histologically identified as well-differentiated adenocarcinomas. The development of ICC is frequently associated with genetic alterations, particularly activating mutations in the KRAS oncogene, which promotes cell growth, and the loss of function in the p53 tumor suppressor gene. The American Joint Committee on Cancer (AJCC) TNM staging system-currently in its seventh edition-is the standard framework for evaluating disease progression and surgical resectability, dividing ICC into four distinct stages.
Request for a detailed insights report on Intrahepatic Cholangiocarcinoma pipeline insights [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Intrahepatic Cholangiocarcinoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Intrahepatic Cholangiocarcinoma Therapeutics Market.
Key Takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report
*
DelveInsight's Intrahepatic Cholangiocarcinoma pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.
*
In January 2022, the US FDA approved the Investigational New Drug (IND) application for KIN-3248, a next-generation pan-FGFR inhibitor being developed by Kinnate Biopharma for intrahepatic cholangiocarcinoma.
*
In February 2022, HUTCHMED launched a Phase Ib/II study in China to evaluate HMPL-453 in combination with chemotherapy or Toripalimab for advanced solid tumors, including intrahepatic cholangiocarcinoma. HMPL-453 is also being tested as a monotherapy in a Phase II clinical trial in China.
*
In May 2021, Kinnate Biopharma Inc. secured USD 35 million in Series A financing to establish a joint venture in China. The venture aims to advance the development of KIN-3248 for the Chinese market. KIN-3248 is an FGFR inhibitor candidate designed to treat patients with intrahepatic cholangiocarcinoma (ICC).
*
Key Intrahepatic Cholangiocarcinoma companies such as Basilea Pharmaceutica, Virogin Biotech Ltd, TriSalus Life Sciences, Forma Therapeutics, Inc, Kinnate Biopharma, Relay Therapeutics, ABL Bio, Hutchison MediPharma, Sirnaomics, Jiangsu Hengrui Medicine, and others are evaluating new drugs for Intrahepatic Cholangiocarcinoma to improve the treatment landscape.
*
Promising Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, and others.
Intrahepatic Cholangiocarcinoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Intrahepatic Cholangiocarcinoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.
Download our free sample page report on Intrahepatic Cholangiocarcinoma pipeline insights [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Intrahepatic Cholangiocarcinoma Emerging Drugs
*
Derazantinib: Basilea Pharmaceutica
Intrahepatic Cholangiocarcinoma Companies
More than 18 prominent companies are actively developing treatments for intrahepatic cholangiocarcinoma. Among these, Basilea Pharmaceutica stands out with its drug candidates being the furthest along in development, currently in Phase II clinical trials.
DelveInsight's report covers around 20+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Intrahepatic Cholangiocarcinoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Intrahepatic Cholangiocarcinoma Therapies and Key Companies: Intrahepatic Cholangiocarcinoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment
- Intrahepatic Cholangiocarcinoma Assessment by Product Type
- Intrahepatic Cholangiocarcinoma By Stage
- Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
- Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
Download Intrahepatic Cholangiocarcinoma Sample report to know in detail about the Intrahepatic Cholangiocarcinoma treatment market @ Intrahepatic Cholangiocarcinoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Intrahepatic Cholangiocarcinoma Current Treatment Patterns
4. Intrahepatic Cholangiocarcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Intrahepatic Cholangiocarcinoma Late-Stage Products (Phase-III)
7. Intrahepatic Cholangiocarcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Intrahepatic Cholangiocarcinoma Discontinued Products
13. Intrahepatic Cholangiocarcinoma Product Profiles
14. Intrahepatic Cholangiocarcinoma Key Companies
15. Intrahepatic Cholangiocarcinoma Key Products
16. Dormant and Discontinued Products
17. Intrahepatic Cholangiocarcinoma Unmet Needs
18. Intrahepatic Cholangiocarcinoma Future Perspectives
19. Intrahepatic Cholangiocarcinoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Intrahepatic Cholangiocarcinoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intrahepatic-cholangiocarcinoma-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-basilea-pharmaceutica-virogin-biotech-ltd-trisalus-life]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Basilea Pharmaceutica, Virogin Biotech Ltd, TriSalus Life here
News-ID: 4127064 • Views: …
More Releases from ABNewswire
Non-Small Cell Lung Cancer Market: Epidemiology, Pipeline Products, Companies Wo …
As per DelveInsight's analysis, the total incident cases of NSCLC in the 7MM were approximately 537,700 in 2024; these cases are estimated to increase by 2034.
Non-Small Cell Lung Cancer emerging therapies such as TransCon hGH, HyTropin (GX-H9), Somatrogon, and others are expected to boost the Non-Small Cell Lung Cancer Market in the upcoming years.
DelveInsight has launched a new report on "Non-Small Cell Lung Cancer - Market Insights, Epidemiology, and Market…
TRK Fusion Cancer Market: Epidemiology, Pipeline Products, Companies Working, De …
TRK fusion cancer treatment, also known as targeted therapy for TRK fusion-positive cancers, is a specialized approach that focuses on a specific genetic alteration found in certain types of cancers. TRK fusions occur when the NTRK genes (NTRK1, NTRK2, or NTRK3) become fused with other genes, resulting in the production of abnormal TRK proteins. These abnormal proteins can drive the growth and spread of cancer.
TRK Fusion Cancer emerging therapies are…
Civil Engineering Services Delivering Trusted Expert Collaboration
Discover how civil engineering services foster trusted expert collaboration, driving innovative, efficient, and sustainable infrastructure solutions. Learn how professional teamwork ensures quality outcomes from planning to project completion.
Miami, Florida, 30 July 2025 As U.S. infrastructure and real estate development accelerate, IBN Technologies is offering a smarter approach to engineering execution. With its scalable and digitized civil engineering services [https://www.ibntech.com/real-estate-and-construction-engineering-services/], the global outsourcing provider supports contractors, developers, and EPC firms in…
Interlock Singapore Unveils Mercury Series: Biometric-Driven Smart Locks Tailore …
SINGAPORE - Interlock Singapore [https://interlock.com.sg/] today announced the launch of its Mercury Series, a quartet of next-generation digital locks designed from the ground up for Singapore's residential market. The lineup comprises two slim-profile door locks-Mercury X5 and Mercury X6-a standalone gate lock (G2), and an exclusive bundle pairing door and gate solutions. Each model integrates advanced biometric authentication, emergency power support and seamless smart-home connectivity, reflecting Interlock's two decades of…
More Releases for Intrahepatic
Intrahepatic Cholangiocarcinoma Market Generated Opportunities, Future Scope 202 …
The intrahepatic cholangiocarcinoma market is estimated to be valued at USD 1.10 billion in 2025 and is expected to reach USD 1.90 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
According to the latest research from CoherentMI, the Intrahepatic Cholangiocarcinoma Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Progressive Familial Intrahepatic Cholestasis Pipeline: Promising Therapies Shap …
The treatment landscape for Progressive Familial Intrahepatic Cholestasis (PFIC), a rare and progressive liver disorder, is evolving rapidly, driven by innovative therapies from leading pharmaceutical and biotech companies. Key players such as Mirum Pharmaceuticals and Vivet Therapeutics are advancing therapeutic options focused on addressing the root causes of cholestasis, including bile acid regulation and hepatic transport. These emerging treatments aim to improve liver function, reduce pruritus, and delay the progression…
Intrahepatic Cholangiocarcinoma Market to See Booming Growth 2025-2032 | Bayer A …
The intrahepatic cholangiocarcinoma market is estimated to be valued at USD 1.02 billion in 2024 and is expected to reach USD 1.87 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
A new report from CoherentMI, titled "Intrahepatic Cholangiocarcinoma Market 2025-2032," offers an in-depth examination of the industry, including valuable insights into the Intrahepatic Cholangiocarcinoma Market's performance. The report covers competitor dynamics, regional…
Intrahepatic Cholangiocarcinoma Pipeline Analysis 2024: FDA Approvals, Clinical …
Intrahepatic Cholangiocarcinoma companies are TransThera Biosciences, J-Pharma Co., Ltd., Nuvectis Pharma, Inc., Merck, RedHill Biopharma, AnHeart Therapeutics, Tyra Biosciences, Inc., Apollomics and others.
(Albany, United States) As per DelveInsight's assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Intrahepatic Cholangiocarcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive…
Transjugular Intrahepatic Portosystemic Shunt (TIPS) Boston Scientific Corporati …
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding and refractory ascites. It involves creating a shunt between the portal and hepatic veins, bypassing the liver to reduce portal pressure. TIPS is performed under fluoroscopic guidance by interventional radiologists. It effectively alleviates symptoms and reduces the risk of complications associated with portal hypertension. TIPS is typically reserved for…
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Type, Shar …
The global progressive familial intrahepatic cholestasis type 2 treatment market size was valued at USD 35 million in 2021 and is projected to reach around USD 550 million in 2030 exhibiting a CAGR of 39.0% in the forecasted period. The rise in the number of drug approvals from the regulatory bodies is anticipated to boost the growth of the progressive familial intrahepatic cholestasis type 2 treatment market during the forecasted…
